Short interest in Polynovo (ASX:PNV) shares is easing. What does this mean?

Is the future looking brighter for Polynovo's stock?

| More on:
most shorted shares webjet

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The amount of Polynovo Ltd (ASX: PNV) shares in the hands of short sellers has dropped recently.

Over the week ending 13 December, Polynovo shares had a 7.5% short interest.

However, in The Motley Fool Australia's latest weekly short selling breakdown, the company's short interest had dropped to 7.2%.

At the time of writing, the Polynovo share price is $1.51, 0.2% lower than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is up 0.4% this morning.

Let's take a look at what the company's falling short interest might mean for its long-term investors.

What does Polynovo's short interest mean for its shares?

The amount of Polynovo's stock held by short sellers has dipped, and it could spell good news for growth investors.

Short sellers aim to profit from a falling share price. Thus, less short selling activity probably means there's greater confidence in the Polynovo share price among some circles.

Perhaps, the rise in apparent confidence is down to its recent performance.

Over the last 30 days, the company's share price has gained 6.6%, boosted by good news released earlier this month.

Polynovo announced it achieved record sales for July and November on 14 December.

It is also recruiting more sales staff in the United States and its search for a new CEO is progressing well.

Additionally, experts are increasingly bullish on the company's stock.

Macquarie recently upgraded its rating for Polynovo's shares to 'outperform', slapping them with a $2.85 price target. That represents an 88% upside on the company's current share price.

As my Foolish colleague, James Mickleboro, recently reported, the broker believes Polynovo's NovoSorb product will be a major catalyst to its growth.

However, the company still sits among the 10 most shorted shares on the ASX. Potentially, due to the stock's performance through 2021.

Since the start of this year, the Polynovo share price has fallen 61%. It's likely many eyes will be on it in the new year in hopes it can correct its tumble.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »